|Articles|July 12, 2023
Are Nitrosamines a Concern for Biologic Manufacturers
Author(s)SGS
This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
3
Generative AI and Adaptive Trials Shape Future Biotech Development
4
Executive Summary: From Molecule to Formulation: A Systematic Approach to Assess Biologics Developability
5